Kidney and Liver Tissue Were Bioprinted Aboard the ISS. Here Is Why It Matters

Manufacturing, 250 miles up

Somewhere above Earth right now, there is human tissue that was built, not grown, in orbit. Auxilium Biotechnologies sent its AMP-1 orbital bioprinter to the International Space Station and came back with kidney, liver and cartilage tissues, plus 28 nerve repair implants.

The work happened during Mission AXLM-3. It was the first mission to manufacture three distinct tissue types in a single spaceflight on one autonomous platform. The tissues returned to Earth on June 17 aboard a SpaceX capsule that splashed down off the California coast.

Why space, and not a lab in San Diego

Gravity is the quiet enemy of tissue engineering. Cells sink. Soft structures sag. The tiny vascular networks that keep lab-grown tissue alive tend to collapse under their own weight. Microgravity removes that problem. What you get is even cell distribution and a structure that holds its shape, something that is nearly impossible to reproduce on the ground.

The kidney and liver tissues used cell designs from the Wake Forest Institute for Regenerative Medicine, one of the leading regenerative medicine centers in the world. Auxilium supplied the manufacturing platform that ran the print in orbit.

What the experts say

Anthony Atala, director of WFIRM and a pioneer in the field, called the result an important step forward. He pointed to the uniform cell distribution achieved on the station as evidence that real medical manufacturing in space is possible, not just hypothetical.

That is the part worth sitting with. This was not a one-off science demo. The platform produced three tissue types and two dozen implants on a single trip. That looks like a process, not an experiment.

The honest caveats

Orbital manufacturing has real limits. As one Axiom Space executive noted back in 2024, the ISS is closer to a worn workshop than a sterile cleanroom. And getting there costs a fortune. Those two facts will shape how fast any of this reaches a clinic.

Still, the direction is clear. A future where certain high-value tissues and devices are built in orbit and shipped back to Earth is no longer science fiction. For regenerative medicine, that changes the math on what can be made, and where.